Abstract
AbstractIndividual chemotherapeutic drugs usually suffered drug resistance in the cancer treatment, and the combination therapy has aroused great interest which can reduce the resistance. Glutamine inhibitor (V9302) and chemotherapy drug doxorubicin (DOX) were combined for the first time to construct a pH‐sensitive multi‐mode synergistic treatment system BSA@CDs‐V9302/DOX. The synergistic rate CI value of the drugs was less than 1, indicating the combination therapy showed a synergistic effect on reducing cancerous cell viability. In addition, compared with the high toxicity and rapid release of free drug DOX and the poor solubility of glutamine inhibitor V9302, the BSA@CDs‐V9302/DOX administration system not only retains the pharmacological activity of V9302 and DOX, but also has an excellent time‐dependence which is more suitable for continuous treatment. BSA@CDs‐V9302/DOX drug delivery system has excellent long‐term tracing ability, which has a high application value in biomedical field.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
